For 3QFY2016, Lupin posted results more or less in line with our expectations. A
higher than expected other income aided the net profit to come in higher than
our expectation. The company posted sales of Rs3,358cr (V/s Rs3,400cr expected),
a growth of 6.8% yoy. On the operating front, the OPM came in at 20.2% (V/s
20.5% expected) V/s 27.0% in 3QFY2015. R&D expenditure during the quarter
was 11.7% of sales V/s 8.3% of sales in 3QFY2015. The net profit came in at
Rs530cr (V/s Rs469cr expected) and V/s Rs601cr in 3QFY2015, a yoy dip of 11.9%.
The higher than expected PAT is on back of higher other income yoy, which came
in at Rs263cr V/s Rs116.1cr in 3QFY2015. Overall, we are Neutral on the stock.
Results below expectations: For 3QFY2016, Lupin posted results more or less in
line with our expectations. A higher than expected other income aided the net
profit to come in higher than our expectation. The company posted sales of
Rs3,358cr (V/s Rs3,400cr expected), a growth of 6.8% yoy. On the operating front,
the OPM came in at 20.2% (V/s 20.5% expected) V/s 27.0% in 3QFY2015. R&D
expenditure during the quarter was 11.7% of sales V/s 8.3% of sales in 3QFY2015.
The net profit came in at Rs530cr (V/s Rs469cr expected) and V/s Rs601cr in
3QFY2015, a yoy dip of 11.9%. The higher than expected PAT is on back of higher
other income yoy, which came in at `263cr V/s Rs116.1cr in 3QFY2015.
Outlook and valuation: We expect Lupin to post a CAGR of 14.6% in net sales
to Rs16,561cr. We expect an earnings CAGR of 13.1% over FY2015-17 to
Rs68.3/share. Currently, the stock is trading at 34.3x and 25.3x its FY2016E and
FY2017E earnings, respectively. We remain Neutral on the stock.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...